Biopharming LEXicon

Production of proteins in plants or animals each provides advantages over protein production in mammalian cells or E. coli, including the capacity to economically scale up and express complex proteins. However, no products produced this way have yet made it to the market.

In February, Biolex Inc. joined a cluster of transgenic pharmaceutical manufacturers with products in the clinic. But it is also accumulating a roster of development collaborations for its plant-based system, which the company is selling as a highly efficient solution for expressing hard-to-make proteins...